Monopar names Prof. Rodney Hicks lead investigator for MNPR-101-Zr Phase 1 trial

Monopar Therapeutics

Professor Rodney Hicks to lead MNPR-101-Zr Phase 1 dosimetry trial in advanced cancer patients.
Trial will use Siemens Biograph Vision Quadra total-body PET/CT, one of the most sensitive clinical scanners.
MNPR-101-Zr targets cancers with high unmet need, including pancreatic and triple-negative breast cancer.
Enrollment expected to begin shortly at Melbourne Theranostic Innovation Centre (MTIC).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.